Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Abroad (travel likely)Recruiting

Conditions

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Adelphi Real World, Bollington, Macclesfield, United Kingdom
Contact: Study coordinator (USA Generic Country) · 0000000000

Study leads

Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Hypertrophic Cardiomyopathy

Abroad (travel likely)Recruiting

Beijing, China · Beijing, China

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Obstructive Hypertrophic Cardiomyopathy

Abroad (travel likely)Recruiting

Anchorage, United States · Tucson, United States

Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Abroad (travel likely)Recruiting

Tokyo, Japan

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy

Abroad (travel likely)Recruiting

Seoul, South Korea · Seoul, South Korea